Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

SPIDIA-RNA: second external quality assessment for the pre-analytical phase of blood samples used for RNA based analyses

F. Malentacchi, M. Pazzagli, L. Simi, C. Orlando, R. Wyrich, K. Günther, P. Verderio, S. Pizzamiglio, CM. Ciniselli, H. Zhang, V. Korenková, L. Rainen, T. Bar, M. Kubista, S. Gelmini,

. 2014 ; 9 (11) : e112293. [pub] 20141110

Language English Country United States

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc15031742

One purpose of the EC funded project, SPIDIA, is to develop evidence-based quality guidelines for the pre-analytical handling of blood samples for RNA molecular testing. To this end, two pan-European External Quality Assessments (EQAs) were implemented. Here we report the results of the second SPIDIA-RNA EQA. This second study included modifications in the protocol related to the blood collection process, the shipping conditions and pre-analytical specimen handling for participants. Participating laboratories received two identical proficiency blood specimens collected in tubes with or without an RNA stabilizer. For pre-defined specimen storage times and temperatures, laboratories were asked to perform RNA extraction from whole blood according to their usual procedure and to return extracted RNA to the SPIDIA facility for further analysis. These RNA samples were evaluated for purity, yield, integrity, stability, presence of interfering substances, and gene expression levels for the validated markers of RNA stability: FOS, IL1B, IL8, GAPDH, FOSB and TNFRSF10c. Analysis of the gene expression results of FOS, IL8, FOSB, and TNFRSF10c, however, indicated that the levels of these transcripts were significantly affected by blood collection tube type and storage temperature. These results demonstrated that only blood collection tubes containing a cellular RNA stabilizer allowed reliable gene expression analysis within 48 h from blood collection for all the genes investigated. The results of these two EQAs have been proposed for use in the development of a Technical Specification by the European Committee for Standardization.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc15031742
003      
CZ-PrNML
005      
20151005124757.0
007      
ta
008      
151005s2014 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1371/journal.pone.0112293 $2 doi
035    __
$a (PubMed)25384019
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Malentacchi, Francesca $u Department of Biomedical Experimental and Clinical Sciences, University of Florence, Florence, Italy.
245    10
$a SPIDIA-RNA: second external quality assessment for the pre-analytical phase of blood samples used for RNA based analyses / $c F. Malentacchi, M. Pazzagli, L. Simi, C. Orlando, R. Wyrich, K. Günther, P. Verderio, S. Pizzamiglio, CM. Ciniselli, H. Zhang, V. Korenková, L. Rainen, T. Bar, M. Kubista, S. Gelmini,
520    9_
$a One purpose of the EC funded project, SPIDIA, is to develop evidence-based quality guidelines for the pre-analytical handling of blood samples for RNA molecular testing. To this end, two pan-European External Quality Assessments (EQAs) were implemented. Here we report the results of the second SPIDIA-RNA EQA. This second study included modifications in the protocol related to the blood collection process, the shipping conditions and pre-analytical specimen handling for participants. Participating laboratories received two identical proficiency blood specimens collected in tubes with or without an RNA stabilizer. For pre-defined specimen storage times and temperatures, laboratories were asked to perform RNA extraction from whole blood according to their usual procedure and to return extracted RNA to the SPIDIA facility for further analysis. These RNA samples were evaluated for purity, yield, integrity, stability, presence of interfering substances, and gene expression levels for the validated markers of RNA stability: FOS, IL1B, IL8, GAPDH, FOSB and TNFRSF10c. Analysis of the gene expression results of FOS, IL8, FOSB, and TNFRSF10c, however, indicated that the levels of these transcripts were significantly affected by blood collection tube type and storage temperature. These results demonstrated that only blood collection tubes containing a cellular RNA stabilizer allowed reliable gene expression analysis within 48 h from blood collection for all the genes investigated. The results of these two EQAs have been proposed for use in the development of a Technical Specification by the European Committee for Standardization.
650    _2
$a odběr vzorku krve $x metody $7 D001800
650    _2
$a GPI-vázané proteiny $x genetika $7 D058851
650    _2
$a stanovení celkové genové exprese $7 D020869
650    _2
$a lidé $7 D006801
650    _2
$a interleukin-1beta $x genetika $7 D053583
650    _2
$a protoonkogenní proteiny c-fos $x genetika $7 D016760
650    _2
$a řízení kvality $7 D011786
650    _2
$a RNA $x krev $x genetika $7 D012313
650    _2
$a TNF decoy receptory $x genetika $7 D053319
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Pazzagli, Mario $u Department of Biomedical Experimental and Clinical Sciences, University of Florence, Florence, Italy.
700    1_
$a Simi, Lisa $u Department of Biomedical Experimental and Clinical Sciences, University of Florence, Florence, Italy.
700    1_
$a Orlando, Claudio $u Department of Biomedical Experimental and Clinical Sciences, University of Florence, Florence, Italy.
700    1_
$a Wyrich, Ralf $u Qiagen GmbH, Hilden, Germany.
700    1_
$a Günther, Kalle $u Qiagen GmbH, Hilden, Germany.
700    1_
$a Verderio, Paolo $u Unit of Medical Statistics, Biometry and Bioinformatics, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Nazionale dei Tumori, Milan, Italy.
700    1_
$a Pizzamiglio, Sara $u Unit of Medical Statistics, Biometry and Bioinformatics, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Nazionale dei Tumori, Milan, Italy.
700    1_
$a Ciniselli, Chiara Maura $u Unit of Medical Statistics, Biometry and Bioinformatics, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Nazionale dei Tumori, Milan, Italy.
700    1_
$a Zhang, Hui $u DiaGenic ASA, Oslo, Norway.
700    1_
$a Korenková, Vlasta $u Institute of Biotechnology, Academy of Sciences of the Czech Republic, Prague, Czech Republic.
700    1_
$a Rainen, Lynne $u Becton Dickinson (BD), Franklin Lakes, New Jersey, United States of America.
700    1_
$a Bar, Tzachi $u Labonnet Ltd, St. Ramat-Hasharon, Israel.
700    1_
$a Kubista, Mikael $u Institute of Biotechnology, Academy of Sciences of the Czech Republic, Prague, Czech Republic; TATAA Biocenter AB, Gothenburg, Sweden.
700    1_
$a Gelmini, Stefania $u Department of Biomedical Experimental and Clinical Sciences, University of Florence, Florence, Italy.
773    0_
$w MED00180950 $t PloS one $x 1932-6203 $g Roč. 9, č. 11 (2014), s. e112293
856    41
$u https://pubmed.ncbi.nlm.nih.gov/25384019 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20151005 $b ABA008
991    __
$a 20151005124940 $b ABA008
999    __
$a ok $b bmc $g 1092618 $s 914868
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2014 $b 9 $c 11 $d e112293 $e 20141110 $i 1932-6203 $m PLoS One $n PLoS One $x MED00180950
LZP    __
$a Pubmed-20151005
Back

Find record

Citation metrics

Archiving options